UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2

The Journal of pharmacology and experimental therapeutics, 2001-02, Vol.296 (2), p.558

2001

Volltextzugriff (PDF)

Lipid biochemical changes detected in normal appearing white matter of chronic multiple sclerosis by spectral coherent Raman imaging

Chemical science (Cambridge), 2018-02, Vol.9 (6), p.1586-1595

2018

Volltextzugriff (PDF)

In vitro effects of cyclooxygenase inhibitors in whole blood of horses, dogs, and cats

American journal of veterinary research, 2001-11, Vol.62 (11), p.1755-1760

2001

Volltextzugriff (PDF)

Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles

The Journal of pharmacology and experimental therapeutics, 1999-08, Vol.290 (2), p.551

1999

Volltextzugriff (PDF)

Differential Roles of DNA Repair Proteins in the MMEJ Phenotype

International journal of radiation oncology, biology, physics, 2012-11, Vol.84 (3), p.S676-S676

2012

Volltextzugriff (PDF)

Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX‐2 inhibitor

British journal of pharmacology, 1997-05, Vol.121 (1), p.105-117

1997

Volltextzugriff (PDF)

The discovery of rofecoxib, [MK 966, VIOXX ®, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5 H)-furanone], an orally active cyclooxygenase-2 inhibitor

Bioorganic & medicinal chemistry letters, 1999-07, Vol.9 (13), p.1773-1778

1999

Volltextzugriff (PDF)

Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: a novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach

The Journal of pharmacology and experimental therapeutics, 1995-09, Vol.274 (3), p.1531

1995

Volltextzugriff (PDF)

Predicting Time to Failure Using the IMM and Excitable Tests

IEEE transactions on systems, man and cybernetics. Part A, Systems and humans, 2007-09, Vol.37 (5), p.630-642

2007

Volltextzugriff (PDF)

A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors

Inflammation research, 1996-02, Vol.45 (2), p.68-74

1996

Volltextzugriff (PDF)

The Problem of Test Latency in Machine Diagnosis

IEEE transactions on systems, man and cybernetics. Part A, Systems and humans, 2008-01, Vol.38 (1), p.88-92

2008

Volltextzugriff (PDF)

Improved statistical methods for hit selection in high-throughput screening

Journal of biomolecular screening, 2003-12, Vol.8 (6), p.634-647

2003

Volltextzugriff (PDF)

Fast Diagnosis With Sensors of Uncertain Quality

IEEE transactions on cybernetics, 2008-08, Vol.38 (4), p.1157-1165

2008

Volltextzugriff (PDF)

The effects of phosphodiesterase type 4 inhibitors on tumour necrosis factor‐ α and leukotriene B 4 in a novel human whole blood assay

British journal of pharmacology, 2009-01, Vol.126 (4), p.979-988

2009

Volltextzugriff (PDF)

Lipid biochemical changes detected in normal appearing white matter of chronic multiple sclerosis by spectral coherent Raman imagingElectronic supplementary information (ESI) available. See DOI: 10.1039/c7sc03992a

2018-02

Volltextzugriff (PDF)

Lipid biochemical changes detected in normal appearing white matter of chronic multiple sclerosis by spectral coherent Raman imaging† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c7sc03992a

Chemical science (Cambridge), 2018-01, Vol.9 (6), p.1586-1595

2018

Volltextzugriff (PDF)

2,3-Diarylcyclopentenones as Orally Active, Highly Selective Cyclooxygenase-2 Inhibitors

Journal of medicinal chemistry, 1999-04, Vol.42 (7), p.1274-1281

1999

Volltextzugriff (PDF)

SAR in the alkoxy lactone series: the discovery of DFP, a potent and orally active COX-2 inhibitor

Bioorganic & medicinal chemistry letters, 1999-08, Vol.9 (15), p.2207-2212

1999

Volltextzugriff (PDF)

Biarylimidazoles as inhibitors of microsomal prostaglandin E2 synthase-1

Bioorganic & medicinal chemistry letters, 2010-12, Vol.20 (23), p.6978-6982

2010

Volltextzugriff (PDF)

A new series of selective COX-2 inhibitors: 5,6-diarylthiazolo[3,2-b][1,2,4]triazoles

Bioorganic & medicinal chemistry letters, 1997-01, Vol.7 (1), p.57-62

1997

Volltextzugriff (PDF)

Quinolines as potent 5-lipoxygenase inhibitors: Synthesis and biological profile of L-746,530

Bioorganic & medicinal chemistry letters, 1998-05, Vol.8 (10), p.1255-1260

1998

Volltextzugriff (PDF)

Statistical and graphical methods for quality control determination of high-throughput screening data

Journal of biomolecular screening, 2003-12, Vol.8 (6), p.624-633

2003

Volltextzugriff (PDF)

NK2 receptors mediate plasma extravasation in guinea‐pig lower airways

British journal of pharmacology, 1993-02, Vol.108 (2), p.383-386

1993

Volltextzugriff (PDF)

In vitro effects and in vivo efficacy of a novel cyclooxygenase-2 inhibitor in dogs with experimentally induced synovitis

American journal of veterinary research, 2004-04, Vol.65 (4), p.503-512

2004

Volltextzugriff (PDF)

Substituted coumarins as potent 5-lipoxygenase inhibitors

Bioorganic & medicinal chemistry letters, 2006-05, Vol.16 (9), p.2528-2531

2006

Volltextzugriff (PDF)

1 – 25 von 127

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(101)
Mit Volltextzugriff
(94)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(76)
Life Sciences & Biomedicine
(64)
Animals
(49)
Biological And Medical Sciences
(42)
Humans
(42)
Pharmacology & Pharmacy
(38)
Medical Sciences
(37)
Pharmacology. Drug Treatments
(35)
Physical Sciences
(32)
Rats
(30)
Chemistry
(29)
Chemistry, Medicinal
(26)
Male
(24)
Bones, Joints And Connective Tissue. Antiinflammatory Agents
(21)
Chemistry, Organic
(21)
Structure-Activity Relationship
(21)
Cyclooxygenase Inhibitors - Pharmacology
(19)
Cyclooxygenase 2
(18)
Cyclooxygenase 2 Inhibitors
(18)
Female
(17)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2

Lipid biochemical changes detected in normal appearing white matter of chronic multiple sclerosis by spectral coherent Raman imaging

In vitro effects of cyclooxygenase inhibitors in whole blood of horses, dogs, and cats

Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles

Differential Roles of DNA Repair Proteins in the MMEJ Phenotype

Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX‐2 inhibitor

The discovery of rofecoxib, [MK 966, VIOXX ®, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5 H)-furanone], an orally active cyclooxygenase-2 inhibitor

Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: a novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach

Predicting Time to Failure Using the IMM and Excitable Tests

A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors

The Problem of Test Latency in Machine Diagnosis

Improved statistical methods for hit selection in high-throughput screening

Fast Diagnosis With Sensors of Uncertain Quality

The effects of phosphodiesterase type 4 inhibitors on tumour necrosis factor‐ α and leukotriene B 4 in a novel human whole blood assay

Lipid biochemical changes detected in normal appearing white matter of chronic multiple sclerosis by spectral coherent Raman imagingElectronic supplementary information (ESI) available. See DOI: 10.1039/c7sc03992a

Lipid biochemical changes detected in normal appearing white matter of chronic multiple sclerosis by spectral coherent Raman imaging† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c7sc03992a

2,3-Diarylcyclopentenones as Orally Active, Highly Selective Cyclooxygenase-2 Inhibitors

SAR in the alkoxy lactone series: the discovery of DFP, a potent and orally active COX-2 inhibitor

Biarylimidazoles as inhibitors of microsomal prostaglandin E2 synthase-1

A new series of selective COX-2 inhibitors: 5,6-diarylthiazolo[3,2-b][1,2,4]triazoles

Quinolines as potent 5-lipoxygenase inhibitors: Synthesis and biological profile of L-746,530

Statistical and graphical methods for quality control determination of high-throughput screening data

NK2 receptors mediate plasma extravasation in guinea‐pig lower airways

In vitro effects and in vivo efficacy of a novel cyclooxygenase-2 inhibitor in dogs with experimentally induced synovitis

Substituted coumarins as potent 5-lipoxygenase inhibitors

Suchergebnisse filtern